The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.
Immunization, HPV Infection, Human Papillomavirus
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
-
University of Texas Medical Branch, Galveston, Texas, United States, 77555
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
27 Years to 45 Years
FEMALE
Yes
The University of Texas Medical Branch, Galveston,
Abbey B Berenson, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Texas
2027-08